Drug Profile
Bemcentinib companion diagnostic - BerGenBio
Alternative Names: BGB 324 companion diagnosticLatest Information Update: 24 Jun 2021
Price :
$50
*
At a glance
- Originator BerGenBio
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Jun 2021 Preclinical trials in Cancer (Diagnosis) in Norway
- 11 Jun 2021 BerGenBio plans registrational trials for Cancer (Diagnosis)